Vortioxetine tablets are indicated for the treatment of major depressive disorder. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) trintellix tablets Takeda Pharmaceuticals, USA, lnc.
According to IQVIA, vortioxetine tablets have an estimated market size of $1249 million for twelve months ending September 2021.
Alembic said it is currently in litigation with H.Lundbeck in Court of Appeals for the Federal Circuit and launch of the product will depend on litigation outcome.
Alembic Pharma has received year to date (YTD) 18 approvals (13 final approvals and 5 tentative approvals) and a cumulative total of 157 ANDA approvals (136 final approvals and 21 tentative approvals) from USFDA.
Shares of Alembic Pharma were trading 0.46% lower at Rs 816.70.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world.
On a consolidated basis, the drug makers net profit dropped 49.22% to Rs 169.29 crore on 11.31% decline in sales to Rs 1,292.32 crore in Q2 FY22 over Q2 FY21.
Powered by Capital Market - Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.